Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)

4 Feb 2013

Abstract excerpt

INTRODUCTION: One of the hallmarks of cancer cells is the inactivation of the p53 pathway either due to mutations in the p53 gene or over-expression of negative regulators, Mdm2 and/or MdmX. Pharmacological disruption of the Mdm2/X-p53 interaction to restore p53 activity is an attractive concept, aiming at a targeted and non-toxic cancer treatment. AREAS COVERED: The introduction covers the biological role of p53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Research and Disease Studies
Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23374098
DOI: 10.1517/13543776.2013.765405

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)PMID 23374098Read ↗

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)Semantic proximity Read ↗

p53–Mdm2 inhibitors: patent review (2009 – 2010)Semantic proximity Read ↗

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)Semantic proximity Read ↗

Patented inhibitors of p53–Mdm2 interaction (2006 – 2008)Semantic proximity Read ↗

Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX InteractionSemantic proximity Read ↗

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trialsSemantic proximity Read ↗

Targeting MDMX for Cancer Therapy: Rationale, Strategies, and ChallengesSemantic proximity Read ↗

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?Semantic proximity Read ↗

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancerSemantic proximity Read ↗

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?Semantic proximity Read ↗

Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be AddressedSemantic proximity Read ↗

Clinical Overview of MDM2/X-Targeted TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.